Rafferty Asset Management LLC lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,275 shares of the biopharmaceutical company’s stock after purchasing an additional 16,353 shares during the quarter. Rafferty Asset Management LLC’s […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective trimmed by JMP Securities from $106.00 to $78.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a market outperform rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the company. […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective lowered by Truist Financial from $86.00 to $70.00 in a research report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on CYTK. JMP Securities cut their price […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target decreased by JMP Securities from $106.00 to $78.00 in a research note issued to investors on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the biopharmaceutical company’s stock. CYTK has been the subject of a number of other reports. Mizuho dropped their […]
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given an average rating of “Moderate Buy” by the seventeen brokerages that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 […]